Ignite Creation Date:
2024-05-06 @ 8:25 PM
Last Modification Date:
2024-10-26 @ 3:27 PM
Study NCT ID:
NCT06370715
Status:
RECRUITING
Last Update Posted:
2024-06-21
First Post:
2024-04-15
Brief Title:
A Study of LY900014 in Adult Participants With Type 2 Diabetes Mellitus in India
Sponsor:
Eli Lilly and Company
Organization:
Eli Lilly and Company
Study Overview
Official Title:
A 26- Week Multicenter Open-Label Single-Arm Phase 4 Study to Assess The Safety of Lyumjev in Adult Patients With Type 2 Diabetes Mellitus in India
Status:
RECRUITING
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to assess the safety of insulin lispro-aabc in adult participants with Type 2 diabetes mellitus in India
The study will last about 33 weeks for each participant including screening 1 week Lead-in period 4 weeks treatment period 26 weeks and follow up period 2 weeks
The study will last about 33 weeks for each participant including screening 1 week Lead-in period 4 weeks treatment period 26 weeks and follow up period 2 weeks
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
True
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| I8B-MC-ITTA | OTHER | Eli Lilly and Company | None |